Potential Efficacy of Pegylated Interferon-α and a Nucleos(t)ide Analogue as Combination Therapy for HBeAg-Positive Chronic Hepatitis B.

Autor: Wi CI; Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA., Kim WR; Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA.; Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA., Gross JB; Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA., Stadheim LM; Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA., Poterucha JJ; Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Jazyk: angličtina
Zdroj: Gut and liver [Gut Liver] 2016 Jul 16; Vol. 10 (4), pp. 611-6.
DOI: 10.5009/gnl14256
Abstrakt: Background/aims: Despite the potent suppression of the hepatitis B virus with modern antiviral agents, only a minority of HBeAg-positive patients achieve hepatitis B e antigen seroconversion. We aimed to explore the potential efficacy of combination therapy consisting of pegylated interferon (p-IFN) and an oral antiviral agent in patients with HBeAgpositive chronic hepatitis B.
Methods: The treatment protocol consisted of p-IFN-α-2a at 180 μg/wk for 48 weeks, with either entecavir or tenofovir added 8 weeks after the initiation of p-IFN and continued for at least 6 months after HBe seroconversion was achieved.
Results: To date, 10 patients have been treated under the protocol (eight adults, mean age 36±8 years; two adolescents, aged 12 and 16 years). All eight adult patients experienced loss of HBeAg at a mean of 72.3±66.9 weeks, including six patients who also developed anti-HBe and one patient who had HBs seroconversion. Although both adolescents remain on therapy, one adolescent had HBs seroconversion without HBe seroconversion. A total of nine of our 10 patients experienced a favorable serological transition.
Conclusions: The combination of p-IFN and a modern oral antiviral agent may be more effective than monotherapy with either class of agent in the treatment of HBeAg-positive chronic hepatitis B patients.
Databáze: MEDLINE
Externí odkaz: